News & Events
Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
SAN DIEGO – July 11, 2025 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2025 financial results...
READ MORECrinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 102,350 shares of its common stock and granted an...
READ MORECrinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline
Crinetics announced eight abstracts from its novel clinical development programs will be presented at the Endocrine Society’s Annual Meeting, ENDO...
READ MORECrinetics Pharmaceuticals to Host R&D Day on June 26, 2025
Crinetics Pharmaceuticals will host an in-person and virtual R&D Day in New York on Thursday, June 26, 2025, from 9:00...
READ MORECrinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 74,000 shares of its common stock and granted an...
READ MORECrinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025
will participate in the Jefferies Global Healthcare Conference, taking place June 3-5, 2025 in New York, NY.
READ MORECrinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025
New Analysis Shows Treatment with Investigational Paltusotine Resulted in Rapid and Durable IGF-1 Control in Surgically Naïve Acromegaly PatientsAdditional Research...
READ MORECrinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 152,475 shares of its common stock and an aggregate...
READ MORECrinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Crinetics Pharmaceuticals reports first quarter 2025 financial results and provided a business update on May 8, 2025 at 4:30PM ET.
READ MORECrinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 124,950 shares of its common stock and an aggregate...
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
